Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
Stock Chart Patterns
Earnings Trading
AI Screener

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. QNCX
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
QNCX
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

QNCX Similar Chart Price Prediction

The price of QNCX is predicted to go up 3.03%, based on the high correlation periods with NBY. The similarity of these two price pattern on the periods is 94.71%.

stocks logo

QNCX

stocks logo

NBY

Up: 3.03%Similarity: 94.71%

QNCX Revenue Forecast

QNCX EPS Forecast

QNCX FAQs

What is bull’s view on QNCX?

QNCX stock has a bullish outlook with analysts projecting significant upside. Rodman & Renshaw set a price target of $50.49, implying a 4,107.50% increase from its recent price of $1.20, driven by optimism around its therapeutic advancements. Brookline Capital also issued a Buy rating with a $9 target, reflecting a 386.49% upside, citing favorable risk-reward as its AIDE platform progresses.

What is bear's view on QNCX?

QNCX stock is bearish due to its current price of $1.91, far below its analyst target of $9-$12, reflecting skepticism about its growth potential despite bullish ratings. Institutional ownership has decreased, signaling reduced confidence from major investors. Additionally, its high projected upside appears speculative, with limited near-term catalysts to support such growth.

QNCX VS S&P500

Ask Intellectia about QNCX

QNCX Analyst's Forecast

Kumaraguru Raja

Brookline Capital

Strong Buy

Price Target

$9

Upside

+386.49%

Brookline initiated coverage of Quince Therapeutics with a Buy rating and $9 price target. Quince is advancing its AIDE technology platform that allows for encapsulation of a drug into a patient's own red blood cells, the analyst tells investors in a research note. The firm sees a favorable risk-reward as EryDex advances through the clinic.
Elemer Piros

Rodman & Renshaw

Strong Buy

Price Target

$11

Upside

+832.2%

Jason Kolbert

EF Hutton

Strong Buy

Price Target

$12

Upside

0%

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free